Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Noteableon Dec 21, 2022 10:57am
199 Views
Post# 35184601

ONCY's pelareorep involves direct dendritic cell activation

ONCY's pelareorep involves direct dendritic cell activation
Reovirus is a multipotent immune agent with oncolytic properties that has demonstrated clinical efficacy in early phase trials in metastatic KRAS mutant colorectal cancer. Its mechanisms of anti-tumor action involve direct dendritic cell activation, by production of proinflammatory cytokines, dendritic cell mediated NK cell activation, which lead to exocytosis of perforin/granzyme and Fas-associated death domain, and activation of T-cells.

- So Yeon Kim1 , Radhashree Maitra2 , Sanjay Goel1,

1Montefiore Medical Center, 1695 Eastchester Road, Bronx, New York 10461, USA; 2Department of Biology, Yeshiva University, 500 West 185th Street, New York 10033, USA; 3Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, New York

https://e-century.us/files/ajtr/13/12/ajtr0136713.pdf
<< Previous
Bullboard Posts
Next >>